Calendar

Calendar: Leadership Development Workshops in Concord, NC

Birthdays

1st – Stacy Kennedy, Cameron Mahaffey

2nd – Jennifer Trejo

3rd – Bub Safrit, Terri Trexler

4th – Chandler Wight

8th – Drew Dantzer

13th – Briana Darga

14th – Jackie Coleman

15th – Sandye Gurley

16th – Lydia Quesenberry

17th – Dakota Irwin

18th – Lucas Locklear

19th – Scott Parrish

21st – Rae Ann Stirewalt

22nd – Sandra Brindle

24th – Teresa Blackwelder

26th – Ann Butler, Becky Wright

27th – Janet London

28th – Karmen Jones

29th – Clint Cox

“Marriage is the most natural state of man, and... the state in which you will find solid happiness.”

~Benjamin Franklin~


7th – Billy & Shirley Moose

20th –Hubert & Peggy Ritchie

21st – Bub & Martha Safrit

NEW DRUG TO FIGHT PANCREATIC CANCER


Pancreatic cancer, although not diagnosed as frequently as other cancers, is one of the deadliest, and currently has few options for treatment. Pancreatitis ranks third behind lung cancer and colorectal cancer as the leading cause of cancer deaths in America. The American Cancer Society estimates that pancreatitis will cause 44,330 deaths in 2018 (both male and female).

Rafael Pharmaceuticals Inc. has developed a new drug which holds promise in fighting pancreatic cancer. The drug, known as CPI-613, works to kill cancer cells by targeting specific enzymes within each cancer cell that are necessary for it to survive. By destroying these enzymes CPI-613 essentially kills the cancer cells and allows the body’s own immunity to get stronger. This drug is currently being tested in clinical trials as a single agent and in combination with other drugs.

CPI-613 is an “orphan drug”, meaning that it has limited potential for profitability (since pancreatitis is not a frequently diagnosed cancer). Orphan drugs usually remain undeveloped by pharmaceutical companies because research and development costs are estimated to be much greater than potential profits. However, Rafael is a Jewish owned company which has included in their mission statement “Our immediate goal is to improve the quality of life of patients with Pancreatic Cancer, which is the deadliest cancer worldwide and has limited treatment options.”   The website further states that Raphael is the Biblical angel of healing, and its literal translation is “God heals”.

 Raphael has instituted a Compassionate Use program to enroll individuals in their clinical trials free of charge. An enrollment form is available on their website which must be completed by the individual’s physician. CPI-613 is also being tested as a treatment option for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), which occurs when something disrupts the production of blood cells in the body.

To learn more about CPI-613 and enrollment in the Compassionate Use program visit raphaelpharma.com. For more information and statistics on pancreatic or other cancers visit www.cancer.org

Bless the Lord, O my soul, and forget not all his benefits: Who forgiveth all thine iniquities; who healeth all thy diseases;

~Psalm 103:2-3~